Yonaxis I.P. Law Group Logo
Category: trademark | Yonaxis I.P. Law Group

Category: "trademark"

of 9

SCOTUS Watch: Bar on Immoral and Scandalous Marks Violates First Amendment

Source: FUCT™, soon to be FUCT® On June 24, 2019, the U.S. Supreme Court handed down Iancu v. Brunetti, dealing with the Lanham Act’s Section 2(a) bars to trademark registration’s collision against...

CannabIP: Second Circuit Refuses to Dismiss CBD Reclassification Case

On May 30, 2019, the Court of Appeals for the Second Circuit in Washington v. Barr, refused to dismiss outright a case where the plaintiffs alleged marijuana’s classification on the Drug Enforcement...

CannabIP: Developments in Cannabis Legalization and Effect on IP

As the new year opens, there have been some developments in legalization of cannabis use, both medicinally and recreationally. First, on the international front, South Korea legalized cannabis for...

CannabIP: State of Federally-Registered Cannabis Marks

|

As we leave 2018 behind us, there were a number of high-profile states and countries which entered the adult-use cannabis marketplace. More cannabis companies, formerly illegal, find themselves now...

Government Shutdown Effect on IP Offices

At midnight on Friday, December 21, 2018, the U.S. government entered a partial shutdown, which means all non-essential federal departments will close operations until funding has been appropriated...

CannabIP: U.S. Patent No. 10,028,987 B1

U.S. Patent No. 10,028,987 (‘987) issued on July 24, 2018, for “Cannabis-Infused Milk.” It was issued to inventor Dylan Pillsbury, of Dos Rios, California. The applicant/assignee is Chocowaska...

Fed Circuit Watch: Dangers of Pro Se Representation – Failure to Understand Procedural Rules

On August 27, 2018, the Court of Appeals for the Federal Circuit issued a rare trademark ruling, Zheng Cai, dba Tai Chi Green Tea Inc. v. Diamond Hong, Inc., dealing with the more mundane aspects of...

CannabIP: FDA Approves First Drug with CBD Active Ingredient

On June 25, 2018, the Food & Drug Administration (FDA) issued a press release in which it approved EPIDIOLEX® for treatment of epilepsy, Lennox-Gastaut syndrome, and Dravet syndrome. Lennox-Gastaut...

CannabIP: Why the USPTO Will Not Register Marks for Cannabis-Related Goods or Services

|

It is perplexing there is still a belief (even among some trademark practitioners) that it is possible to file federal trademark applications at the U.S. Patent and Trademark Office for...

of 9